MATHEUS FREITAS CARDOSO DE AZEVEDO
Índice h a partir de 2011
5
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
47 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 47
bookPart Doença celíaca(2023) PIRES, Thales Simões Nobre; AZEVEDO, Matheus Freitas Cardoso de- Fatal Presentation of Thrombotic Cutaneous Gangrene Associated With Acute Severe Colitis(2023) BARROS, Luisa Leite; PRADO, Rita de Cassia Parente; FERREIRA, Lucas Fortes Portela; AZEVEDO, Matheus Freitas Cardoso de; OBA, Jane; CARLOS, Alexandre de Souza; DAMIAO, Aderson Omar Mourao Cintra
bookPart Doença inflamatória intestinal(2017) AZEVEDO, Matheus Freitas Cardoso de; ANDRADE, Guilherme MarquesbookPart Colite pseudomembranosa(2023) MELLO, Munique Kurtz de; AZEVEDO, Matheus Freitas Cardoso de; MARZINOTTO, Maira Andrade NacibemconferenceObject Clinical features of thrombosis in patients with Crohn's disease followed at the Clinical Hospital of the University of Sao Paulo, Brazil(2016) ANDRADE, A. Ribas; BARROS, L. Leite; AZEVEDO, M.; SIPAHI, A.; LEITE, A. Zonetti de Arruda- Anti-TNF Therapy in Elderly Patients With Inflammatory Bowel Disease in a Tuberculosis-Endemic Country(2023) BARROS, Luisa Leite; AZEVEDO, Matheus Freitas Cardoso de; CARLOS, Alexandre de Souza; LOPES, Paula De Azevedo; FUJITA, Andre Okuhara; BRITO, Daniela Sanches; KAMADA, Daniela Midori; PRADO, Rita de Cassia Parente; ANDRADE, Julia Carvalho De; OBA, Jane; DAMIAO, Aderson Omar Mourao Cintra
- Prevalence of dysplasia and colorectal cancer in Ulcerative Colitis patients from a referral center in Latin America(2021) JUNIOR, R. S. F.; CARVALHO, M. F.; SILVA, J. C.; BARROS, L. L.; AZEVEDO, M. F. C.; CARLOS, A. D. S.; OBA, J.; HASHIMOTO, C. L.; CANCADO, E. L. R.; DAMIAO, A. O. M. C.; SIPAHI, A. M.
- Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction-A Prospective Trial(2023) GARCIA, Karoline Soares; AZEVEDO, Matheus Freitas Cardoso de; CARLOS, Alexandre de Sousa; BARROS, Luisa Leite; OBA, Jane; SOBRADO JUNIOR, Carlos Walter; SIPAHI, Aytan Miranda; ALVES, Olivia Duarte de Castro; NAVARRO-RODRIGUEZ, Tomas; PARRA, Rogerio Serafim; CHEBLI, Julio Maria Fonseca; CHEBLI, Liliana Andrade; FLORES, Cristina; VIEIRA, Andrea; CEARA, Christianne Damasceno Arcelino do; QUEIROZ, Natalia Sousa Freitas; DAMIAO, Aderson Omar Mourao CintraTherapeutic drug monitoring (TDM) during induction therapy with anti-tumor necrosis factor drugs has emerged as a strategy to optimize response to these biologics and avoid undesired outcomes related to inadequate drug exposure. This study aimed to describe clinical, biological, and endoscopic remission rates at six months in Brazilian inflammatory bowel disease (IBD) patients following a proactive TDM algorithm guided by IFX trough levels (ITL) and antibodies to IFX (ATI) levels during induction, at week six. A total of 111 IBD patients were prospectively enrolled, excluding those previously exposed to the drug. ITL & GE; 10 & mu;g/mL was considered optimal. Patients with suboptimal ITL (<10 & mu;g/mL) were guided according to ATI levels. Those who presented ATI & LE; 200 ng/mL underwent dose intensification in the maintenance phase, and patients with ATI > 200 ng/mL discontinued IFX. In our study, proactive TDM was associated with persistence in the IFX rate at six months of 82.9%. At that time, rates of clinical, biological, and endoscopic remission in patients under IFX treatment were 80.2%, 73.9%, and 48.1%, respectively. Applying a simplified TDM-guided algorithm during induction seems feasible and can help improve patients' outcomes in clinical practice.
- Long-term effectiveness and safety of ustekinumab in bio-naive and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study(2022) PARRA, Rogerio Serafim; CHEBLI, Julio Maria Fonseca; QUEIROZ, Natalia Sousa Freitas; DAMIAO, Aderson Omar Mourao Cintra; AZEVEDO, Matheus Freitas Cardoso de; CHEBLI, Liliana Andrade; BERTGES, Erika Ruback; ALVES JUNIOR, Antonio Jose Tiburcio; AMBROGINI JUNIOR, Orlando; SILVA, Bianca Loyo Pona Schiavetti da; LUBINI, Marcio; BAFUTTO, Mauro; FLORES, Cristina; VILELA, Eduardo Garcia; BORATTO, Sandra Felice; GASPARETTI JUNIOR, Newton Luiz Tricarico; STEINWURZ, Flavio; CARVALHO, Nayara Salgado; FERES, Omar; ROCHA, Jose Joaquim Ribeiro daBackground The effectiveness of ustekinumab (UST) in the treatment of Crohn's disease (CD) has been demonstrated in the pivotal Phase 3 UNITI 1 and 2 and IM-UNITI studies in both anti-TNF-naive and anti-TNF-exposed patients. Given the selective nature of pivotal trial designs, real-world effectiveness and safety studies are warranted. We report our experience with UST treatment in a large, real-world multicenter cohort of Brazilian patients with CD. Methods We performed a retrospective multicenter study including patients with CD, predominantly biologically refractory CD, who received UST. The primary endpoint was the proportion of patients in clinical remission at weeks 8, 24 and 56. Possible predictors of clinical and biological response/remission and safety outcomes were also assessed. Results Overall, 245 CD (mean age 39.9 [15-87]) patients were enrolled. Most patients (86.5%) had been previously exposed to biologics. According to nonresponder imputation analysis, the proportions of patients in clinical remission at weeks 8, 24 and 56 were 41.0% (n = 98/239), 64.0% (n = 153/239) and 39.3% (n = 94/239), respectively. A biological response was achieved in 55.4% of patients at week 8, and 59.3% were in steroid-free remission at the end of follow-up. No significant differences in either clinical or biological remission were noted between bio-naive and bio-experienced patients. Forty-eight patients (19.6%) presented 60 adverse events during the follow-up, of which 8 (13.3%) were considered serious adverse events (3.2% of 245 patients). Overall, a proximal disease location, younger age, perianal involvement, and smoking were associated with lower rates of clinical remission over time. Conclusions UST therapy was effective and safe in the long term in this large real-life cohort of Brazilian patients with refractory CD, regardless of previous exposure to other biological agents.
- Safety of anti-TNF introduction following tuberculosis treatment in Inflammatory Bowel Disease patients in an endemic area(2021) AZEVEDO, M. F. C. D.; JUSTUS, F. F.; LIMA, C. C. G.; GARCIA, K. S.; BARROS, L. L.; OBA, J.; CARLOS, A. D. S.; MILANI, L. R.; SIPAHI, A. M.; DAMIAO, A. O. M. C.; QUEIROZ, N. S. F.